Phase III Trial Finds Tirzepatide Significantly Reduces BMI in Adolescents With Obesity
In a 72-week Phase III trial, the weight-loss medication tirzepatide reduced body mass index by an average of 18.5% in adolescents with obesity. More than half of the participants treated with the drug no longer met the clinical threshold for obesity by the end of the study.
Share this story
A highly anticipated Phase III clinical trial has demonstrated that the dual-receptor agonist tirzepatide produces substantial weight loss in adolescents living with obesity. The findings offer a potential new pharmacological intervention for a demographic with historically limited treatment options.[1][2]
Presented on Sunday at the ObesityWeek 2026 conference in Washington, D.C., the SURMOUNT-ADOLESCENTS trial results were simultaneously published in the Journal of the American Medical Association. The data revealed an 18.5% mean reduction in body mass index over 72 weeks.[1][3]
"Tirzepatide-treated participants had greater reductions in body weight compared with placebo, and 48.1% achieved at least 20% reduction in BMI," wrote lead author Aaron S. Kelly of the University of Minnesota Medical School. The treatment was accompanied by broad improvements in cardiometabolic risk factors.[1]
Shifting the Clinical Threshold
The magnitude of the BMI reduction observed in the trial is rarely seen in pediatric obesity interventions. While the tirzepatide group experienced an 18.5% decline in BMI, participants receiving a placebo saw their BMI increase by 0.5% over the same 18-month period.[1][2]
For the 160 adolescents enrolled in the study, this percentage translated to profound physical changes. Participants receiving the active medication lost an average of approximately 40 pounds from an average baseline weight of roughly 240 pounds.[2][3]
Perhaps the most striking outcome was the shift in clinical categorization. By week 72, over half of the adolescents taking tirzepatide—53.5%—no longer met the clinical threshold for obesity, defined as a BMI below the 95th percentile for their age and sex.[1][3]
In stark contrast, only 7.1% of the adolescents in the placebo group managed to drop below the clinical obesity threshold through lifestyle interventions alone. These results establish a remarkably high efficacy bar for next-generation weight management therapies in younger populations.[1][4]
The medication, marketed by Eli Lilly under the brand name Zepbound for adults, pairs a healthy lifestyle intervention with a once-weekly injection. It targets both GIP and GLP-1 receptors to regulate appetite and caloric intake.[1][4]
Tracking the Adolescent Cohort
The SURMOUNT-ADOLESCENTS study enrolled patients aged 12 to under 18 years across more than 30 research centers. The cohort was 61.9% female, with an average age of 14.6 years and a mean baseline BMI of 38.6, placing most in the severe obesity category.[1][2]
Researchers designed the 72-week trial to evaluate both the primary endpoint of overall BMI reduction and ten key secondary outcomes. These secondary measures included specific changes in waist circumference, total body weight, and self-reported improvements in daily physical functioning.[1][5]
Nearly 80% of the adolescents treated with tirzepatide achieved a BMI reduction of at least 5%, compared to just 28.5% of those on placebo. Furthermore, 71.4% of the treatment group saw their BMI drop by at least 10%.[1]
The trial specifically targeted adolescents who had obesity, or who were overweight and suffering from at least one obesity-related health complication. Researchers cautioned that these specific findings may not directly apply to adolescents diagnosed with type 2 diabetes.[1][2]
Eli Lilly is actively presenting these detailed datasets at ObesityWeek 2026 to support its push to expand Zepbound's approved indications. The company hopes to secure regulatory approval to offer the medication to younger patients in the near future.[2][3]
Monitoring Safety and Maturation
Safety remains a primary concern for pediatricians evaluating long-term pharmacological treatments for teenagers. The most frequently reported side effects in the SURMOUNT-ADOLESCENTS trial were gastrointestinal issues, primarily nausea and vomiting, which aligns with the safety profile observed in adult trials.[1][2]
Among the 108 participants who received at least one dose of tirzepatide, ten individuals—representing 9.3% of the treatment group—discontinued the medication due to adverse events. No participants in the placebo group dropped out for safety reasons.[1]
To manage these gastrointestinal symptoms, 22.2% of the adolescents on tirzepatide utilized antiemetic medications to control nausea, compared to just 3.9% in the placebo group. Antidiarrheal use was slightly higher in the treatment arm as well.[1]
A critical metric for adolescent trials is the impact of significant weight loss on normal physical development. The research team closely monitored the participants' height standard deviation scores and their progression through the Tanner stages of puberty.[1]
"Despite substantial BMI reduction, height standard deviation score remained stable, and pubertal progression was similar between the treatment groups over 72 weeks," Kelly's research group noted. This suggests the medication does not disrupt expected growth or sexual maturation.[1]
Cardiometabolic and Systemic Benefits
The benefits of tirzepatide extended well beyond simple weight reduction, addressing systemic health issues that often accompany severe pediatric obesity. The treatment group demonstrated significant improvements in both systolic and diastolic blood pressure over the 18-month study period.[1]
Participants also experienced marked improvements in their overall lipid profiles and baseline glycemic control. The medication effectively lowered total cholesterol, LDL cholesterol, and triglycerides, while simultaneously raising levels of beneficial HDL cholesterol, reducing long-term cardiovascular risks.[1]
Fasting glucose and fasting insulin levels improved significantly among the adolescents receiving the weekly injection. These metabolic shifts are crucial for preventing the early onset of type 2 diabetes, a condition increasingly diagnosed in pediatric populations.[1][5]
"Obesity care is about more than numbers on the scale," said Kenneth Custer, president of Lilly Cardiometabolic Health, during the conference. He emphasized that the new evidence reflects a broader view of care that includes clinical outcomes for varied obesity-related conditions.[3][4]
The trial also measured the impact of weight loss on the adolescents' quality of life. Participants reported notable improvements in physical comfort and body esteem, highlighting the psychological benefits of effective obesity management during formative teenage years.[1][3]
Expanding Pediatric Treatment Options
If approved for adolescents, Zepbound would enter a market where its primary competitor, Novo Nordisk, already maintains a strong foothold. Novo's GLP-1 receptor agonist, Wegovy, received regulatory approval for adolescent obesity treatment in December 2022.[1][2]
The 18.5% BMI reduction seen with tirzepatide in adolescents closely mirrors the 20% body weight reduction previously observed in the adult SURMOUNT-1 trial. This consistency across age groups provides strong clinical validation for the drug's underlying mechanism of action.[1]
Pediatric endocrinologists have been closely watching these datasets to fill a critical gap in adolescent obesity care. The ability to intervene effectively before adulthood could prevent decades of chronic disease, fundamentally altering the trajectory of pediatric health.[3]
Eli Lilly's broader ObesityWeek 2026 presentations also highlighted other investigational therapies, including retatrutide for sleep apnea and osteoarthritis. However, the adolescent data remains a focal point for clinicians desperate for highly effective, safe interventions for their youngest patients.[3][4]
Broader Portfolio Developments
Beyond the adolescent trial, Eli Lilly utilized the ObesityWeek 2026 platform to showcase its wider cardiometabolic pipeline. The company presented Phase 3 data for retatrutide, an investigational triple-receptor agonist, demonstrating severe sleep apnea reductions.[3][5]
In the TRIUMPH-1 trial, adults with moderate-to-severe obstructive sleep apnea and obesity saw their apnea-hypopnea index drop by an average of 36.1 events per hour. This represents a 60.6% reduction over 80 weeks of treatment.[3][5]
In the TRIUMPH-1 trial, adults with moderate-to-severe obstructive sleep apnea and obesity saw their apnea-hypopnea index drop by an average of 36.1 events per hour.
Key points
- Tirzepatide reduced body mass index by an average of 18.5% over 72 weeks in adolescents with obesity, compared to a 0.5% increase for placebo.
- More than half of the teenagers treated with the medication no longer met the clinical threshold for obesity by the end of the trial.
- The treatment group experienced significant improvements in cardiovascular risk factors, including blood pressure, cholesterol, and fasting insulin levels.
- Researchers confirmed that the substantial weight loss did not disrupt the adolescents' expected physical growth or pubertal maturation.
What we don’t know
- How long the adolescents will need to remain on the medication to maintain their weight loss into adulthood.
- Whether the long-term cardiovascular benefits observed in adult trials will fully translate to patients who begin treatment in their teenage years.
- When the FDA might officially approve Zepbound for use in adolescent populations.
How we got here
December 2022
Novo Nordisk's Wegovy receives FDA approval for the treatment of adolescent obesity.
November 2023
The FDA approves tirzepatide, marketed as Zepbound, for chronic weight management in adults.
November 2026
Eli Lilly presents the Phase III SURMOUNT-ADOLESCENTS trial results at the ObesityWeek conference.
- Pediatric Endocrinologists
- Emphasize the urgent need for highly effective pharmacological tools to treat severe adolescent obesity before it causes irreversible long-term complications.
- Pharmaceutical Industry Analysts
- Focus on the competitive market dynamics, noting that an adolescent approval would help Eli Lilly challenge Novo Nordisk's existing foothold in younger demographics.
- Clinical Trial Researchers
- Highlight the importance of rigorous safety monitoring, particularly ensuring that significant weight loss does not disrupt normal adolescent growth and pubertal maturation.
Perspectives this story doesn't cover
- Adolescent patients and their families
- Health insurance providers evaluating coverage costs
Sources
[1]MedPage TodayPediatric EndocrinologistsTirzepatide Cuts BMI in Adolescents With Obesity in Phase III Trial
Read on MedPage Today →
[2]Seeking AlphaPharmaceutical Industry AnalystsLilly's Zepbound shows promise in teen obesity trial
Read on Seeking Alpha →
[3]Clinical Trial VanguardClinical Trial ResearchersLilly presents obesity drug data at ObesityWeek 2026
Read on Clinical Trial Vanguard →
[4]FidelityPharmaceutical Industry AnalystsLilly to present new data across Zepbound, Foundayo, EloraTZP and retatrutide at ObesityWeek 2026, moving obesity care beyond the scale
Read on Fidelity →
[5]Investing.comPharmaceutical Industry AnalystsEli Lilly showcases obesity and diabetes trial data at ObesityWeek 2026
Read on Investing.com →
More in Health
See all →Medical Ethics
Guinea-Bissau Halts Controversial US-Funded Hepatitis B Vaccine Trial on Newborns
6 sources
Asthma Management
Inhaler Spacers Decelerate 30-Meter-Per-Second Aerosols to Shift Asthma Medication Into the Lungs
4 sources
Infant Microbiome
Absence of Bacterial Colonization Resistance Allows Clostridium botulinum Spores in Honey to Germinate and Produce Neurotoxin in Infants
5 sources
Global Health Trends
WHO Reports Global Life Expectancy Rebounds to Pre-Pandemic Levels as Chronic Illness Expands
7 sources
Comments
Every angle. Every day.
Get Health stories with full source coverage and perspective breakdowns, free every day.




